| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9283282 | TOLMAR | Sustained release polymer |
Oct, 2018
(5 years ago) | |
| US8486455 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US9254307 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US9539333 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US9914802 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(6 months ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395293 | TOLMAR | Biodegradable implant precursor |
Sep, 2013
(10 years ago) | |
| US5599552 | TOLMAR | Biodegradable polymer composition |
Feb, 2014
(10 years ago) | |
| US6773714 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US6565874 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US6626870 | TOLMAR | Stoppering method to maintain sterility |
Mar, 2020
(4 years ago) | |
| US8840916 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
Eligard Kit is owned by Tolmar.
Eligard Kit contains Leuprolide Acetate.
Eligard Kit has a total of 13 drug patents out of which 12 drug patents have expired.
Expired drug patents of Eligard Kit are:
- US6395293
- US5599552
- US6773714
- US6565874
- US6626870
- US8840916
- US9283282
- US8486455
- US9254307
- US9539333
- US9914802
- US8470359
Eligard Kit was authorised for market use on 13 February, 2003.
Eligard Kit is available in powder;subcutaneous dosage forms.
Eligard Kit can be used as palliative treatment of prostate cancer, method of treating cancer.
The generics of Eligard Kit are possible to be released after 22 December, 2041.
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 13 February, 2003
Treatment: Method of treating cancer; Palliative treatment of prostate cancer
Dosage: POWDER;SUBCUTANEOUS
ELIGARD KIT family patents
